Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • NEWS AND VIEWS

Severe hepatitis outbreak in children linked to AAV2 virus

Since 2022, more than 1,000 cases of childhood hepatitis with no known cause have been reported. The discovery of adeno-associated virus 2 in the blood and livers of such children might provide an explanation.
  1. Frank Tacke

    1. Frank Tacke is in the Department of Hepatology and Gastroenterology, Charité – Universitätsmedizin Berlin, 13353 Berlin, Germany.

    View author publications

    You can also search for this author in PubMed  Google Scholar

Paediatricians first began to report a concerning wave of acute severe hepatitis — a disease involving liver inflammation — in children in spring 2022. This spate of cases, which now numbers more than 1,000 (see go.nature.com/42dpfv4), had no known cause, unlike most cases of paediatric hepatitis. The cases were often serious, with 7.3% of affected children needing a liver transplant1. Writing in Nature, three groups now independently provide evidence that infection by adeno-associated virus 2 (AAV2) is linked to this wave2–4. Their work is likely to spark debate, and could influence disease management.

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Learn more

Prices may be subject to local taxes which are calculated during checkout

Nature 617, 471-472 (2023)

doi: https://doi.org/10.1038/d41586-023-00570-8

References

  1. Alexander, E. C. & Deep, A. JAMA Netw. Open 5, e2237091 (2022).

    Article  PubMed  Google Scholar 

  2. Ho, A. et al. Nature 617, 555–563 (2023).

    Article  Google Scholar 

  3. Morfopoulou, S. et al. Nature 617, 564–573 (2023).

    Article  Google Scholar 

  4. Servellita, V. et al. Nature 617, 574–580 (2023).

    Article  Google Scholar 

  5. Gutierrez Sanchez, L. H. et al. N. Engl. J. Med. 387, 620–630 (2022).

    Article  PubMed  Google Scholar 

  6. Kelgeri, C. et al. N. Engl. J. Med. 387, 611–619 (2022).

    Article  PubMed  Google Scholar 

  7. Karpen, S. J. N. Engl. J. Med. 387, 656–657 (2022).

    Article  PubMed  Google Scholar 

  8. Sant’Anna, T. B. & Araujo, N. M. Virol. J. 19, 173 (2022).

    Article  PubMed  Google Scholar 

  9. Shen, W., Liu, S. & Ou, L. Front. Immunol. 13, 1001263 (2022).

    Article  PubMed  Google Scholar 

  10. Brevini, T. et al. Nature 615, 134–142 (2022).

    Article  PubMed  Google Scholar 

Download references

Competing Interests

F.T.’s laboratory has received research funding at Charité – Universitätsmedizin Berlin from Allergan, Bristol Myers Squibb, Gilead and Inventiva. F.T. has acted as a consultant for AstraZeneca, Allergan, Bayer, Boehringer Ingelheim, Galapagos, Gilead, Intercept, Inventiva, Madrigal, Novartis, Novo Nordisk and Pfizer.

Subjects

Latest on:

Nature Careers

Jobs

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing

Search

Advanced search

Quick links